Umbilical cord blood is an alternative hematopoietic stem cell source for patients with
hematologic diseases who can be cured by allogeneic hematopoietic cell transplantation …

Placental structures, capable to persist in a genetically foreign organism, are a natural
model of allogeneic engraftment carrying a number of distinctive properties. In this review …

The year 2009 marked the fiftieth anniversary of the first successful allogeneic
haematopoietic stem cell transplant (HSCT). The field of HSCT has pioneered some of the …

Umbilical cord blood transplantation (UCBT) has been performed in the clinic for over 30
years. The biological and immunological characteristics of umbilical cord blood (UCB) have …

The Sickle Cell Unrelated Donor Transplant Trial (SCURT trial) of the Blood and Marrow
Transplant Clinical Trials Network (BMT CTN) is a phase II study of the toxicity and efficacy …

Unrelated donor cord blood transplantation (CBT) results in disease-free survival
comparable to that of unrelated adult donor transplantation in patients with hematologic …

Haematopoietic cell transplantation (HCT) is the most widely used form of cellular therapy. It
is the only known cure for some haematological malignancies and has recently been used …

Graft failure is a major complication after unrelated cord blood transplantation. Presence of
HLA-antibodies before cord blood transplantation may impact graft failure. To analyze the …

Selection of a suitable graft for allogeneic hematopoietic stem cell transplantation involves
consideration of both donor and recipient characteristics. Of primary importance is sufficient …

Optimal cord blood (CB) unit selection is critical to maximize the likelihood of successful
engraftment and survival after CB transplantation (CBT). However, unit selection can be …